Validating the translational potential of BTZ in Onc-p53 NSCLC cells, BTZ and the BH3-mimetic navitoclax were synergistically cytotoxic in Onc-p53 but not in WTp53 cells in vitro, and BTZ effectively limited the growth of Onc-p53 NSCLC xenografts when combined with navitoclax and carboplatin (a standard-of-care chemotherapeutic in NSCLC) in vivo. The gene discussed is TP53; the disease is non-small cell lung carcinoma.